Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • MJFF Research Grant, 2012
    Regulated GDNF Gene Therapy: A Novel Regulatory System Based on Protein Degradation

    Promising Outcomes of Original Grant:
    We have developed lentiviral vectors that can express functional GDNF both in the cell culture dish and in the brain of pre-clinical models. These vectors can be...

  • Rapid Response Innovation Awards, 2012
    Ceruloplasmin Deamidation in Parkinson’s Disease Cerebrospinal Fluid: Gain of Pro-adhesive Function

    Objective/Rationale:
    We demonstrated that Ceruloplasmin (Cp), an enzyme present in cerebrospinal fluid (CSF), is oxidized in the CSF of PD patients. Among oxidative modifications, the asparagine...

  • Neurotrophic Factors Challenge, 2012
    Pre-clinical Validation of a Nurr1 Agonist for Neuroprotection in Parkinson’s Disease

    Objective/Rationale:             

    Studies in PD patients have shown that increased cellular levels of α-syn are associated with reduced levels of Nurr1, and that mutations in the Nurr1 gene that have...

  • Resource: Utilizing Samples from the Arizona Parkinson’s Dis, 2012
    Neurotrophic and Autophagic Markers in Parkinson’s Disease: Implications for Disease-modifying Strategies

    Objective/Rationale:             

    GDNF is a potent survival factor for dopamine (DA) neurons, effective in standard neurotoxin models of PD, but recent studies show that GDNF is unable to rescue DA...

  • Rapid Response Innovation Awards, 2012
    Evaluation of the Effects of Human Cell Derived GM1 Ganglioside in the MPTP Lesioned Pre-clinical Model of Parkinson's Disease

    Objective/Rationale:             

    The objective of this study is to evaluate the effects of human cell derived GM1 (hGM1) ganglioside in the treatment of a pre-clinical model of Parkinsons disease (PD)...

  • Dyskinesia LEAPS, 2012
    Development of L-745,870, a Selective D4 Receptor Antagonist, for the Treatment of Levodopa-induced Dyskinesia

    Objective/Rationale: 
    In the 1980s and 90s a novel drug, L-745,870 was developed for the treatment of psychosis in schizophrenia. L-745,870 has excellent characteristics for a drug, and a selective...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.